Jacobus J. M. van der Hoeven

2351P Whole genome sequencing of AYA patients Open

Paul Roepman, Jos P. M. van Putten, Immy Riethorst, M. Baksi, H.E. Nienhuis , et al. · 2023

Pros and cons of streamlining and use of computerised clinical decision support systems to future-proof oncological multidisciplinary team meetings Open

Janneke E. W. Walraven, Rob H.A. Verhoeven, Jacobus J. M. van der Hoeven, R. van der Meulen, V.E.P.P. Lemmens , et al. · 2023

Introduction Nowadays nearly every patient with cancer is discussed in a multidisciplinary team meeting (MDTM) to determine an optimal treatment plan. The growth in the number of patients to be discussed is unsustainable. Streamlining and …

Supplementary Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry Open

Rik J. Verheijden, Anne M. May, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel , et al. · 2023

Suppl. tab. S1 | Multivariable Cox regression of baseline factors associated with overall survival in all first-line checkpoint inhibitor treated patients Suppl. tab. S2 | Multivariable Cox regression of baseline factors associated with ov…

Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry Open

Rik J. Verheijden, Anne M. May, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel , et al. · 2023

Purpose:Unleashing the immune system by PD-1 and/or CTLA-4 blockade can cause severe immune-related toxicity necessitating immunosuppressive treatment. Whether immunosuppression for toxicity impacts survival is largely unknown.Experimental…

Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry Open

Rik J. Verheijden, Anne M. May, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel , et al. · 2023

Purpose:Unleashing the immune system by PD-1 and/or CTLA-4 blockade can cause severe immune-related toxicity necessitating immunosuppressive treatment. Whether immunosuppression for toxicity impacts survival is largely unknown.Experimental…

Supplementary Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry Open

Rik J. Verheijden, Anne M. May, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel , et al. · 2023

Suppl. tab. S1 | Multivariable Cox regression of baseline factors associated with overall survival in all first-line checkpoint inhibitor treated patients Suppl. tab. S2 | Multivariable Cox regression of baseline factors associated with ov…

Practice variation in re-resection for recurrent glioblastoma: A nationwide survey among Dutch neuro-oncology specialists Open

Mark P. van Opijnen, Filip De Vos, Rob J.A. Nabuurs, Tom J. Snijders, Rishi Nandoe Tewarie , et al. · 2023

Background Despite current best treatment options, a glioblastoma almost inevitably recurs after primary treatment. However, in the absence of clear evidence, current guidelines on recurrent glioblastoma are not well-defined. Re-resection …

Phase 1 Study to Evaluate the Safety of Reducing the Prophylactic Dose of Dexamethasone around Docetaxel Infusion in Patients with Prostate and Breast Cancer Open

Rieneke T. Lugtenberg, Stefanie de Groot, Danny Houtsma, Vincent O. Dezentjé, Annelie Vulink , et al. · 2023

Background: There is little evidence that supports the registered high dose of dexamethasone used around docetaxel. However, this high dose is associated with considerable side effects. This study evaluates the feasibility of reducing the …

Facilitators and barriers to conducting an efficient, competent and high-quality oncological multidisciplinary team meeting Open

Janneke E. W. Walraven, Rob H.A. Verhoeven, R. van der Meulen, Jacobus J. M. van der Hoeven, V.E.P.P. Lemmens , et al. · 2023

Background Optimal oncological care nowadays requires discussing every patient in a multidisciplinary team meeting (MDTM). The number of patients to be discussed is rising rapidly due to the increasing incidence and prevalence of cancer an…

Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics Open

Luuk J. Schipper, Kris G. Samsom, Pétur Snæbjörnsson, Thomas Battaglia, Linda J.W. Bosch , et al. · 2022

Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study Open

Mark P. van Opijnen, Marike L. D. Broekman, Filip De Vos, Edwin Cuppen, Jacobus J. M. van der Hoeven , et al. · 2022

The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer Open

Janneke E. W. Walraven, Theodora M. Ripping, Jorg R. Oddens, Bas W.G. van Rhijn, Catharina A. Goossens‐Laan , et al. · 2022

Objectives To investigate the role of specialised genitourinary multidisciplinary team meetings (MDTMs) in decision‐making and identify factors that influence the probability of receiving a treatment plan with curative intent for patients …

Factors influencing the quality and functioning of oncological multidisciplinary team meetings: results of a systematic review Open

Janneke E. W. Walraven, Olga L. van der Hel, Jacobus J. M. van der Hoeven, V.E.P.P. Lemmens, Rob H.A. Verhoeven , et al. · 2022

Preparing tomorrow’s medical specialists for participating in oncological multidisciplinary team meetings: perceived barriers, facilitators and training needs Open

Janneke E. W. Walraven, R. van der Meulen, Jacobus J. M. van der Hoeven, V.E.P.P. Lemmens, Rob H.A. Verhoeven , et al. · 2022

Discontinuation of <span>anti‐PD</span>‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice Open

Michiel C.T. van Zeijl, Alfons J.M. van den Eertwegh, Michel W.J.M. Wouters, Liesbeth C. de Wreede, Maureen J.B. Aarts , et al. · 2021

There is no consensus on the optimal treatment duration of anti‐PD‐1 for advanced melanoma. The aim of our study was to gain insight into the outcomes of anti‐PD‐1 discontinuation, the association of treatment duration with progression and…

Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach Open

Alicia K. Morgans, Annelotte van Bommel, Caleb Stowell, Janet L. Abrahm, Ethan Basch , et al. · 2021

BackgroundThere are no universally monitored outcomes relevant to men with advanced prostate cancer, making it challenging to compare health outcomes between populations.ObjectiveWe sought to develop a standard set of outcomes relevant to …

Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry Open

Anouk Jochems, Esther Bastiaannet, Maureen J.B. Aarts, Alexander C.J. van Akkooi, Franchette W.P.J. van den Berkmortel , et al. · 2021

Patients with metastatic melanoma ≥75 years are less frequently treated, but when treated there is no statistical significant increase in toxicity and only a borderline statistical significant difference in Melanoma Specific Survival was s…

Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics Open

Paul Roepman, Ewart de Bruijn, Stef van Lieshout, Lieke Schoenmaker, Mirjam C. Boelens , et al. · 2021

Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry Open

Michiel C.T. van Zeijl, Liesbeth C. de Wreede, Alfons J.M. van den Eertwegh, Michel W.J.M. Wouters, Anouk Jochems , et al. · 2020

Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial Open

Rieneke T. Lugtenberg, Stefanie de Groot, Ad A. Kaptein, Maarten J. Fischer, Elma Meershoek‐Klein Kranenbarg , et al. · 2020

Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE) Open

Kris G. Samsom, Linda J.W. Bosch, Luuk J. Schipper, Paul Roepman, Ewart de Bruijn , et al. · 2020

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial Open

Stefanie de Groot, Rieneke T. Lugtenberg, Danielle Cohen, Marij J.P. Welters, Ilina Ehsan , et al. · 2020

Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs Open

B Leeneman, Carin A. Uyl‐de Groot, Maureen J.B. Aarts, Alexander C.J. van Akkooi, Franchette W.P.J. van den Berkmortel , et al. · 2020

Immunotherapeutic and targeted drugs improved survival of patients with metastatic melanoma. There is, however, a lack of evidence regarding their healthcare costs in clinical practice. The aim of our study was to provide insight into real…

High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes Open

Tessa G. Steenbruggen, Lars C. Steggink, Caroline Seynaeve, Jacobus J. M. van der Hoeven, Maartje J. Hooning , et al. · 2020

ClinicalTrials.gov Identifier: NCT03087409.

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry Open

Rik J. Verheijden, Anne M. May, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel , et al. · 2020

Purpose: Unleashing the immune system by PD-1 and/or CTLA-4 blockade can cause severe immune-related toxicity necessitating immunosuppressive treatment. Whether immunosuppression for toxicity impacts survival is largely unknown. Experiment…

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease Open

Rik J. Verheijden, Anne M. May, Christian U. Blank, Astrid A.M. van der Veldt, Marye J. Boers‐Sonderen , et al. · 2020

Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH? Open

Maartje G. Schouwenburg, Karijn P.M. Suijkerbuijk, Rutger H.T. Koornstra, Anouk Jochems, Michiel C.T. van Zeijl , et al. · 2019

The prognosis of patients with advanced melanoma has improved dramatically. However, the clinical outcomes of patients with highly elevated serum lactate dehydrogenase (LDH) remain very poor. The aim of this study was to explore whether pa…

Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands Open

Michiel C.T. van Zeijl, Michel W.J.M. Wouters, Alfons J.M. van den Eertwegh, L. C. de Wreede, Maureen J.B. Aarts , et al. · 2019

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01) Open

Stefanie de Groot, Hanno Pijl, Ayoub Charehbili, Saskia van de Ven, Vincent T.H.B.M. Smit , et al. · 2019

Effects of short-term fasting on cancer treatment Open

Stefanie de Groot, Hanno Pijl, Jacobus J. M. van der Hoeven, Judith R. Kroep · 2019

Growing preclinical evidence shows that short-term fasting (STF) protects from toxicity while enhancing the efficacy of a variety of chemotherapeutic agents in the treatment of various tumour types. STF reinforces stress resistance of heal…

Jacobus J. M. van der Hoeven YOU? Author Swipe